Articles

Radiotherapy for metastatic colorectal cancer: When is it worth it?

BJMO - volume 16, issue 7, november 2022

P. Populaire MD, S. Isebaert PhD, K. Haustermans MD, PhD

SUMMARY

Colorectal cancer is a prevalent cancer in Belgium. Unfortunately, many of these patients will develop metastases at some point in their disease. However, given the new therapeutic options, the prognosis of these patients is better than before. Local ablation of metastases is among these therapeutic options. This concept of metastasis-directed therapy (MDT) is generally accepted for oligometastatic disease. It can be accomplished by a multitude of techniques, including surgery, radiofrequency and microwave ablation, but also radiotherapy (RT). This review addressed the rationale and application of RT within this context.

(BELG J MED ONCOL 2022;16(7):336–42)

Read more

The potential of proton therapy in oesophageal cancer treatment

BJMO - volume 13, issue 1, february 2019

M. Thomas , M. Lambrecht MD, PhD, K. Haustermans MD, PhD

Radiotherapy has become the standard of care in the curative treatment of locally advanced oesophageal cancer. Advanced radiotherapy techniques, such as intensity-modulated radiotherapy, can reduce doses to normal tissues resulting in lower toxicities and an improved outcome. The unique physical features of proton beam therapy has tremendous potential to further spare organs at risk. Besides the clear dosimetric advantages of proton beam therapy in oesophageal cancer, there is evidence that supports a clinical benefit. However, results from prospective randomised trials are awaited. To maximise the cost-effectiveness of this new technology, patient selection for proton beam therapy using validated multifactorial normal tissue complication probability models is suggested. However, this requires international collaboration to prospectively collect data of patients treated with proton beam therapy.

(BELG J MED ONCOL 2019;13(1):11–15)

Read more